Published in N Engl J Med on October 21, 1999
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B | NCT00524173
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa | NCT02060162
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther (2012) 1.81
Preventing and treating hepatitis B infection. BMJ (2004) 1.80
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
Antiviral resistance and hepatitis B therapy. Hepatology (2009) 1.67
Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther (2010) 1.61
Pathogenesis of hepatitis B virus infection. World J Gastroenterol (2007) 1.47
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother (2002) 1.45
Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Dynamics of hepatitis B virus resistance to lamivudine. J Virol (2006) 1.38
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology (2009) 1.35
Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol (2001) 1.33
Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells. J Virol (2005) 1.32
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut (2005) 1.28
Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol (2006) 1.25
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. Cancer (2007) 1.21
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother (2001) 1.18
Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol (2006) 1.17
Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm (2010) 1.17
Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol (2014) 1.14
Hepatitis B virus genotyping among chronic hepatitis B individuals with resistance to Lamivudine in shahrekord, iran. Jundishapur J Microbiol (2014) 1.11
Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency. Mol Ther (2008) 1.10
Lamivudine in the treatment of acute hepatitis B. N Engl J Med (2000) 1.10
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat (2006) 1.09
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Sexually acquired hepatitis. Sex Transm Infect (2002) 1.09
Tautomerism in drug discovery. J Comput Aided Mol Des (2010) 1.05
Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol (2002) 1.05
Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci (2005) 1.05
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother (2002) 1.05
The economics of treating chronic hepatitis B in Asia. Hepatol Int (2008) 1.04
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother (2002) 1.03
Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World J Gastroenterol (2003) 1.02
Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J (2011) 1.01
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int (2008) 1.01
Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother (2004) 1.00
TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review). Int J Oncol (2014) 1.00
Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother (2010) 0.99
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep (2011) 0.99
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver (2011) 0.97
Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. Indian J Med Res (2011) 0.96
The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol (2004) 0.95
Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci (2008) 0.95
Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother (2002) 0.94
Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int (2010) 0.93
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses (2010) 0.93
The promise of gene therapy in gastrointestinal and liver diseases. Gut (2003) 0.92
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med (2007) 0.91
A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol (2007) 0.90
Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol (2013) 0.90
Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol (2012) 0.89
Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy. J Clin Microbiol (2005) 0.88
Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol (2009) 0.88
The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag (2007) 0.88
Prevalence of HBV and HCV among blood donors in Kosovo. Virol J (2009) 0.88
Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol (2002) 0.88
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol (2006) 0.88
Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol (2004) 0.88
Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther (2013) 0.87
Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int (2010) 0.87
Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol (2013) 0.87
DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol (2009) 0.87
Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol (2015) 0.86
Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J Gastroenterol (2004) 0.86
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother (2006) 0.86
Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol (2012) 0.86
Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int (2008) 0.86
Current and future directions for treating hepatitis B virus infection. World J Hepatol (2015) 0.85
Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol (2006) 0.84
Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrob Agents Chemother (2002) 0.84
Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol (2007) 0.84
Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. J Gastroenterol (2007) 0.84
Management of chronic hepatitis B in pregnancy. World J Gastroenterol (2012) 0.83
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol (2014) 0.83
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol (2014) 0.83
Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med (2011) 0.83
Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method. J Clin Microbiol (2005) 0.83
Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol (2015) 0.83
High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial. BMC Gastroenterol (2005) 0.83
Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob Agents Chemother (2003) 0.83
A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci (2012) 0.82
Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J (2007) 0.82
Current role of Lamivudine regarding therapeutic response and resistance in children with chronic hepatitis B. Pediatr Gastroenterol Hepatol Nutr (2013) 0.82
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother (2001) 0.82
Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. J Zhejiang Univ Sci B (2005) 0.82
Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case. Virol J (2010) 0.82
Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med (2011) 0.82
Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol (2012) 0.82
Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett (2013) 0.81
Development of cell cultures that express hepatitis B virus to high levels and accumulate cccDNA. J Virol Methods (2010) 0.81
Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol (2011) 0.81
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell (2001) 4.27
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 4.14
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med (1995) 3.86
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med (1989) 3.45
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology (2000) 3.42
Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology (2000) 3.42
"Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet (1994) 3.33
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Molecular virology and pathogenesis of hepatitis B. Lancet (1993) 3.27
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 3.11
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med (1992) 3.01
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg (1999) 2.79
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med (1988) 2.68
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 2.49
Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol (1999) 2.40
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Formation of the atrioventricular septal structures in the normal mouse. Circ Res (1998) 2.21
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology (1988) 2.20
Indeterminate hepatitis C. Lancet (1993) 2.17
Failure of Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population. Ann Intern Med (1987) 2.14
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Hepatitis C-associated hepatocellular carcinoma. Hepatology (1990) 2.07
Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis (1995) 2.07
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis (2000) 2.06
Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol (2000) 2.06
Clinical relevance of hepatitis B viral mutations. Hepatology (2000) 2.03
Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol (1995) 2.00
Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Invest (1972) 2.00
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 1.97
Methane in lake kivu: new data bearing on its origin. Science (1973) 1.92
Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology (1985) 1.90
The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc (1996) 1.89
Mount st. Helens volcano: recent and future behavior. Science (1975) 1.89
The Oxford Clinical Cataract Classification and Grading System. Int Ophthalmol (1986) 1.87
Acute hepatitis C. Hepatology (2001) 1.82
Large cystic lesions of the liver in adults: a 15-year experience in a tertiary center. J Am Coll Surg (2001) 1.79
Regulation of left-right asymmetry by thresholds of Pitx2c activity. Development (2001) 1.77
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
THE AGE OF SALT MARSH PEAT AND ITS RELATION TO RECENT CHANGES IN SEA LEVEL AT BARNSTABLE, MASSACHUSETTS. Proc Natl Acad Sci U S A (1962) 1.76
Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg (2001) 1.72
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965-66. JAMA (1969) 1.67
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant (2010) 1.67
The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation (1995) 1.67
Waves of mouse Lunatic fringe expression, in four-hour cycles at two-hour intervals, precede somite boundary formation. Curr Biol (1998) 1.65
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62
A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med (1987) 1.61
Clinical and serological features of human herpesvirus-6 infection in three adults. Lancet (1988) 1.61
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther (2004) 1.61
Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C. J Clin Apher (1991) 1.61
Efficacy of hepatitis B immune serum globulin after accidental exposure. Preliminary report of the Veterans Administration Cooperative Study. Lancet (1975) 1.59
Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med (2005) 1.58
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 1.55
Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med (2001) 1.55
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med (1993) 1.54
A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet (1995) 1.54
Lamivudine therapy of WHV-infected woodchucks. Virology (1998) 1.52
Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology (1993) 1.52
The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr (1991) 1.51
Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut (2003) 1.51
Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology (1995) 1.51
The comparative survivals of alcoholics versus nonalcoholics after distal splenorenal shunt. Ann Surg (1978) 1.49
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. Circulation (1978) 1.48
Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol (1993) 1.48
Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology (1999) 1.48
Prognostic factor in neuroblastoma. Cancer (1987) 1.47
A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl (2001) 1.47
Indian childhood cirrhosis in an American child. Gastroenterology (1992) 1.47
Iridotomy with a ruby laser. Br J Ophthalmol (1973) 1.47
Biometry of the crystalline lens in early-onset diabetes. Br J Ophthalmol (1990) 1.47
Atrial development in the human heart: an immunohistochemical study with emphasis on the role of mesenchymal tissues. Anat Rec (2000) 1.46